NCT00093041View on ClinicalTrials.gov

Zalutumumab in Head and Neck Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 1, 2003

Primary Completion Date

January 12, 2005

Study Completion Date

January 12, 2005

Conditions
Head and Neck Neoplasms
Interventions
DRUG

Zalutumumab

Weekly infusion

Trial Locations (5)

2100

Rigshospitalet, Copenhagen Ø

5000

Odense Universitetshospital, Odense

8000

Århus Kommunehospital, Århus C

221 85

Universitets Sjukhuset i Lund, Lund

751 85

Uppsala Akademiska Sjukhus, Uppsala

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY

NCT00093041 - Zalutumumab in Head and Neck Cancer | Biotech Hunter | Biotech Hunter